Arvaya Healthcare Expands Footprint via Share-Swap Acquisition

Shares Allotted: 38,71,854 | Total Transaction Value: Rs 15.49 crore

Reader Takeaway: Strategic acquisition via share-swap broadens medical portfolio, though equity dilution warrants monitoring for long-term earnings impact.

What just happened

Arvaya Healthcare Limited has approved the preferential allotment of 38,71,854 equity shares to the shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL). This transaction was conducted as a share-swap, meaning the shares were issued for consideration other than cash. The issue price was set at Rs 40 per share, comprising a face value of Rs 10 and a premium of Rs 30. A total of 47 non-promoter investors participated in this allotment, and the shares are subject to a mandatory lock-in period as prescribed by SEBI (ICDR) regulations.

Why this matters

The acquisition represents a strategic integration into the specialized gastroenterology space. By utilizing a share-swap mechanism, Arvaya Healthcare has successfully expanded its business capacity without depleting its liquid cash reserves. This move signals a deliberate effort to scale the company's healthcare services through inorganic growth.

Equity Capital Impact

The allotment has resulted in a change to the company’s capital structure. The paid-up equity capital has moved from Rs 48.02 crore to Rs 51.89 crore. The total number of shares has increased from 4,80,21,857 to 5,18,93,711.

What to track next

Investors should focus on the operational integration of the Sushodha Institute of Gastroenterology. Key updates to watch for include how this new unit contributes to the company's quarterly revenue and whether the integration leads to improved margins or new service capabilities in the gastroenterology vertical.